Abbott Park, Illinois (ots/PRNewswire) - - First expansion into new disease for rheumatoid arthritis drug HUMIRA Abbott (NYSE: ABT) announced it has simultaneously submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) and a supplemental Biologics License Application ...
London (ots/PRNewswire) - AstraZeneca today announced that the initial analysis of the primary endpoint of Study 709, IRESSA Survival Evaluation in Lung cancer (ISEL) with 1692 patients has been conducted, and shows that IRESSA failed to significantly prolong survival in comparison to placebo in the overall ...
London (ots/PRNewswire) - - 'Redefining Hope and Beauty' Campaign Surpasses All Expectations Breast cancer charities from around the world are today celebrating the success of the world's first truly global breast cancer awareness campaign - 'Redefining Hope and Beauty'. In the first few weeks since its historic launch, the campaign has already surpassed ...
Montreal, Canada (ots/PRNewswire) - Galileo Genomics Inc., a Montreal-based gene and drug target discovery company, announced today it raised CDN$11.1 million in additional equity funding to close the 2nd tranche of its Series B financing. This round, originally targeted at CDN$10 million, is the latest in a ...
San Antonio Breast Cancer Symposium, California (ots/PRNewswire) - - New Results From Two Phase II Trials Demonstrate Efficacy and Tolerability for 'Faslodex' Following Progression on aromatase Inhibitor Therapy - Webcast of Data Available on www.astrazenecapressoffice.com Important new data from two studies presented at the 27th Annual San Antonio Breast ...
San Antonio, Texas (ots/PRNewswire) - - New Trial Results Offer More Choice for More Women With Breast Cancer The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Completed Treatment Analysis(1),(2): Presented by Professor Anthony Howell and simultaneously published via fast-track peer-review in ...
San Antonio, Texas (ots/PRNewswire) - - 'The Latest Hormonal Treatment Options in the Breast Cancer Continuum' - An AstraZeneca Sponsored Webcast From the 2004 San Antonio Breast Cancer Symposium This webcast will announce key new data for 'FASLODEX' and 'ARIMIDEX' that is being presented at the 27th San Antonio Breast Cancer Symposium (SABCS), 8 - 11 December. The webcast explores the latest developments in the treatment of postmenopausal women with early ...
Laval, Quebec (ots/PRNewswire) - LAB International Inc. (TSX: LAB, Frankfurt: LD9.F, XETRA: LD9.DE), an integrated drug development company focused on the inhalation market, today announced that its shares are available for trading on the Regulated Unofficial Market (Freiverkehr) of the Frankfurt Stock Exchange and on XETRA(R), the Deutsche Borse AG electronic trading system. The inclusion of LAB's securities in the ...
Deerfield, Illinois (ots/PRNewswire) - Baxter International Inc. (NYSE: BAX) announced today that it has voluntarily suspended enrollment in the Phase II/III clinical study currently underway in Europe of its PreFluCel influenza vaccine, due to a higher than expected rate of mild fever and associated symptoms in the clinical trial participants. "In developing a ...
London (ots/PRNewswire) - Medicsight Inc. (OTC Bulletin Board: MSHT) announced today that on November 30, 2004 it forwarded its application to transfer the Company's listing from the OTC Bulletin Board to the American Stock Exchange to Cohen Specialists LLC, who deposited it with the American Stock Exchange on ...
Laval, Canada (ots/PRNewswire) - - Malnutrition in Patients With Late Pre-end-stage Chronic Renal Failure Selected as Clinical Indication for Trial LAB International Inc. (TSX: LAB), an integrated drug development company focused on the inhalation market, today announced that, after completion of a successful dose-response trial, it has selected the first clinical indication for which it intends to evaluate ...
London (ots/PRNewswire) - - Spontaneity and Self-Confidence Cited as Reasons Why Men Preferred Cialis In Second Study A recent analysis demonstrated that 80 percent of men who took 20 mg Cialis(R)(1) (tadalafil) for the treatment of erectile dysfunction (ED) and had successful intercourse reported ...
London (ots/PRNewswire) - - Patients with moderate-to-severe ED and comorbid conditions respond to Cialis Cialis(R)(1) (tadalafil) may effectively treat erectile dysfunction (ED) in men with a variety of comorbidities that can make the condition more difficult to manage, according to new studies released ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that a Canadian Phase III trial for its lead immunosuppressive drug candidate, ISA247 for the treatment of moderate to severe psoriasis has commenced. As of today, a total of 21 patients have been enrolled and dosing has begun. The Phase III trial will be performed over a twenty-four week period at thirty-three centers across Canada involving a ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that the Company received a No Objection Letter from Health Canada for the commencement of a Phase III trial for its lead immunosuppressive drug candidate, ISA247. The trial will be performed over a twenty-four week period at thirty- ...
Lausanne (ots) - IMD, a world leader in executive education, announced on December 1st 2004 that Dr. Matti Alahuhta has been elected Chairman of the IMD Foundation Board, replacing Heini Lippuner, who has served as Chairman elect of IMD's Foundation Board since 1999, Vice Chairman elect since 1996, and member since 1989. Mr. Lippuner, who has served as Director ...
Tampere, Finland and London (ots/PRNewswire) - Inion, a rapidly growing company focused on the development of novel biodegradable medical implants, is very pleased to announce that its ordinary shares have been admitted to the Official List of the UK Listing Authority and will begin unconditional trading today on London's Main Market under the symbol IIN.L. The Company's listing in London takes place in connection ...
Basel, Switzerland, November 30 (ots/PRNewswire) - Roche and Genentech, Inc., announced today that Avastin(TM) (bevacizumab, rhuMAb-VEGF), a new innovative anti-angiogenesis drug, has shown for the first time that it significantly increases survival in patients with metastatic colorectal cancer when used in ...
Santa Fe, New Mexico, November 29 (ots/PRNewswire) - Bioreason, Inc., announced today the release of ClassPharmer(TM) Suite Lite, a new edition of the company's software system to increase success in the hits-to-leads-to-clinic process within drug discovery. ClassPharmer(TM) Suite Lite is available from ...
Laval, Quebec, November 29 (ots/PRNewswire) - LAB International Inc. (TSX: LAB), an integrated drug development company focused on the inhalation market, today announced that LAB Pharma, its drug development subsidiary headquartered in Finland, has secured approximately CAD$4.6 million (2.95 million euros) to ...
Tampere, Finland, November 26 (ots/PRNewswire) - Inion, a rapidly-growing medical device company that focuses on the development and commercialisation of novel biodegradable implants for the orthopaedic fixation market, today announces that it has successfully completed its Initial Public Offering in connection with listing on the London Stock Exchange. The shares ...
Madrid, Spain, November 25 (ots/PRNewswire) - - Aplidin(R) now in Phase II trials in both solid and haematological cancers PharmaMar, the biopharmaceutical company specialising in cancer therapy, today announces that its marine derived anti-tumour agent, Aplidin(R), has commenced Phase II clinical trials in haematological malignancies, including studies in Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) ...
London, November 23 (ots/PRNewswire) - - Agfa, Vital Images, and Viatronix to Use Medicsight Software Medicsight Inc.'s (OTC Bulletin Board: MSHT) majority owned subsidiary, Medicsight PLC ("Medicsight"), announced today that it has signed letters of intent with Agfa-Gevaert N.V. and Viatronix and a ...
Seattle, November 19 (ots/PRNewswire) - Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; Nuovo Mercato) today announced that it is responding to inquiries from the U.S. Attorney for the Western District of Washington in connection with previously disclosed promotional practices for TRISENOX. CTI is fully cooperating with the U.S. Attorney in this matter. About Cell Therapeutics, Inc. Headquartered in Seattle, CTI ...
Madrid, November 19 (ots/PRNewswire) - PharmaMar announced today that Aplidin(R) (1), its second marine-derived compound in clinical development, was granted orphan drug status by the European Commission for the treatment of multiple myeloma (MM) following adoption of a positive opinion by the Committee for ...
Glasgow, Scotland, November 18 (ots/PRNewswire) - - RESIST-2 Data Demonstrate Efficacy in Treatment-Experienced Patient Population New tipranavir pivotal Phase III data show that a statistically significant higher percentage of treatment-experienced HIV-positive patients taking tipranavir therapy achieved treatment response versus those taking other ...
Princeton, New Jersey, November 17 (ots/PRNewswire) - Clearview Projects, Inc. announced today that Jan Wolpert has joined the company as President & CEO. Most recently, Jan was the president, founder and principal owner of Wolpert Associates, Inc., a strategic management consulting firm specializing in corporate development matters. With offices in both New Jersey and California, Clearview Projects provides ...
Montreal, November 17 (ots/PRNewswire) - - Exceptional exposure for Nstein Technologies Nstein Technologies Inc. (TSX-V: EIN), an emerging leader in new Business Intelligence (BI) solutions, received international exposure today at the United Nations at the official launch of the enhanced version of the ...
PEROS SYSTEMS TECHNOLOGIES INC
ST- NICOLAS, Canada, November 16 (ots/PRNewswire) - Under a cooperative research agreement signed in December of 2003 the USDA-ARS and PerOs Systems Technologies Inc, conducted tests combining PerOs' oral drug delivery technology, Oralject(TM), with the USDA-ARS' vaccine developed against the streptococcal ...
London, November 16 (ots/PRNewswire) - New research published today in the European Journal of Cancer (EJC) (1) indicates that an overwhelming 78 per cent of healthy premenopausal women would prefer goserelin ('Zoladex (TM)') therapy to chemotherapy if they were to develop oestrogen-receptor positive (ER+) early ...